RAS-dependent RAF-MAPK hyperactivation by pathogenic RIT1 is a therapeutic target in Noonan syndrome–associated cardiac hypertrophy
暂无分享,去创建一个
F. McCormick | M. Swain | A. Stephen | P. Castel | D. Simanshu | J. Columbus | Alice Cheng | Antonio Cuevas-Navarro | T. Turbyville | Richard A. Van | Matthew J. Sale | S. Messing | Morgan Wagner | Stephanie Mo | Madeline R Allison
[1] Neville E. Sanjana,et al. Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition , 2023, The Journal of experimental medicine.
[2] J. Bjerre,et al. Succesful MEK-inhibition of severe hypertrophic cardiomyopathy in RIT1-related Noonan Syndrome. , 2022, European journal of medical genetics.
[3] O. Abdel-Wahab,et al. Impaired Proteolysis of Noncanonical RAS Proteins Drives Clonal Hematopoietic Transformation , 2022, Cancer discovery.
[4] G. Jiménez,et al. Cross-species analysis of LZTR1 loss-of-function mutants demonstrates dependency to RIT1 orthologs , 2022, bioRxiv.
[5] D. Xie,et al. Elevated expression of RIT1 hyperactivates RAS/MAPK signal and sensitizes hepatocellular carcinoma to combined treatment with sorafenib and AKT inhibitor , 2021, Oncogene.
[6] M. Ladanyi,et al. Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer , 2021, Nature Communications.
[7] D. Esposito,et al. KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation , 2021, Nature Communications.
[8] Amy D. Migliori,et al. The RIT1 C-terminus associates with lipid bilayers via charge complementarity , 2021, Comput. Biol. Chem..
[9] F. McCormick,et al. The RAS GTPase RIT1 compromises mitotic fidelity through spindle assembly checkpoint suppression , 2020, Current Biology.
[10] F. McCormick,et al. The molecular functions of RIT1 and its contribution to human disease. , 2020, The Biochemical journal.
[11] A. Garcia,et al. Anionic Lipids Impact RAS-Binding Site Accessibility and Membrane Binding Affinity of CRAF RBD-CRD. , 2020, Biophysical journal.
[12] F. McCormick,et al. The duality of human oncoproteins: drivers of cancer and congenital disorders , 2020, Nature Reviews Cancer.
[13] Hongyan Chen,et al. LZTR1 inactivation promotes MAPK/ ERK pathway activation in glioblastoma by stabilizing oncoprotein RIT1 , 2020 .
[14] M. Holderfield,et al. Homogeneous Dual-Parametric-Coupled Assay for Simultaneous Nucleotide Exchange and KRAS/RAF-RBD Interaction Monitoring , 2020, Analytical chemistry.
[15] D. Esposito,et al. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling. , 2019, Molecular cell.
[16] P. Alexander,et al. Structures of N-terminally processed KRAS provide insight into the role of N-acetylation , 2019, Scientific Reports.
[17] B. Gelb,et al. Hypertrophic Cardiomyopathy in Noonan Syndrome Treated by MEK-Inhibition. , 2019, Journal of the American College of Cardiology.
[18] Y. Matsubara,et al. New Noonan syndrome model mice with RIT1 mutation exhibit cardiac hypertrophy and susceptibility to β-adrenergic stimulation-induced cardiac fibrosis , 2019, EBioMedicine.
[19] F. McCormick,et al. RIT1 oncoproteins escape LZTR1-mediated proteolysis , 2019, Science.
[20] R. Ghirlando,et al. KRAS Prenylation Is Required for Bivalent Binding with Calmodulin in a Nucleotide-Independent Manner , 2019, Biophysical journal.
[21] F. McCormick,et al. SHOC2–MRAS–PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis , 2018, Proceedings of the National Academy of Sciences.
[22] G. Rosenberger,et al. RIT1 controls actin dynamics via complex formation with RAC1/CDC42 and PAK1 , 2018, PLoS genetics.
[23] E. Braunwald,et al. Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. , 2017, Circulation research.
[24] Frank McCormick,et al. RAS Proteins and Their Regulators in Human Disease , 2017, Cell.
[25] Gaelen T. Hess,et al. Genome-scale measurement of off-target activity using Cas9 toxicity in high-throughput screens , 2017, Nature Communications.
[26] M. Landthaler,et al. An immediate–late gene expression module decodes ERK signal duration , 2017, Molecular Systems Biology.
[27] M. Porotto,et al. Quantitative analysis of molecular partition towards lipid membranes using surface plasmon resonance , 2017, Scientific Reports.
[28] Mohammad Reza Ahmadian,et al. The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions , 2016, PloS one.
[29] M. Ikura,et al. Biochemical Classification of Disease-associated Mutants of RAS-like Protein Expressed in Many Tissues (RIT1)* , 2016, The Journal of Biological Chemistry.
[30] I. Mihalek,et al. Mutations in RIT1 cause Noonan syndrome – additional functional evidence and expanding the clinical phenotype , 2016, Clinical genetics.
[31] O. Migita,et al. Spectrum of mutations and genotype–phenotype analysis in Noonan syndrome patients with RIT1 mutations , 2016, Human Genetics.
[32] Yoichi Matsubara,et al. Recent advances in RASopathies , 2015, Journal of Human Genetics.
[33] Xiwen Ma,et al. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.
[34] Woonghee Lee,et al. NMRFAM-SPARKY: enhanced software for biomolecular NMR spectroscopy , 2014, Bioinform..
[35] J Wala,et al. Oncogenic RIT1 mutations in lung adenocarcinoma , 2014, Oncogene.
[36] Toshihiko Ogura,et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. , 2013, American journal of human genetics.
[37] S. Miyano,et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies , 2013, Leukemia.
[38] K. Flaherty,et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. , 2012, The Lancet. Oncology.
[39] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[40] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[41] Parbati Biswas,et al. Position-specific propensities of amino acids in the β-strand , 2010, BMC Structural Biology.
[42] M. Barbacid,et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival , 2010, The EMBO journal.
[43] T. Meyer,et al. PI(3,4,5)P3 and PI(4,5)P2 Lipids Target Proteins with Polybasic Clusters to the Plasma Membrane , 2006, Science.
[44] F. Studier,et al. Protein production by auto-induction in high density shaking cultures. , 2005, Protein expression and purification.
[45] G. Shi,et al. Rit Contributes to Nerve Growth Factor-Induced Neuronal Differentiation via Activation of B-Raf-Extracellular Signal-Regulated Kinase and p38 Mitogen-Activated Protein Kinase Cascades , 2005, Molecular and Cellular Biology.
[46] F. McCormick,et al. Signaling Specificity by Ras Family GTPases Is Determined by the Full Spectrum of Effectors They Regulate , 2004, Molecular and Cellular Biology.
[47] H. Rindt,et al. Protein kinase C isoform expression and activity in the mouse heart. , 2001, American journal of physiology. Heart and circulatory physiology.
[48] E. Nånberg,et al. Role of phosphoinositide 3OH‐kinase in autocrine transformation by PDGF‐BB * , 2001, Journal of cellular physiology.
[49] J. Hancock,et al. Compartmentalization of Ras proteins. , 2001, Journal of cell science.
[50] Giulio Superti‐Furga,et al. Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation , 1999, The EMBO journal.
[51] P. Warne,et al. Role of Phosphoinositide 3-OH Kinase in Cell Transformation and Control of the Actin Cytoskeleton by Ras , 1997, Cell.
[52] C. Marshall,et al. Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases* , 1997, The Journal of Biological Chemistry.
[53] D. Zack,et al. Rin, a Neuron-Specific and Calmodulin-Binding Small G-Protein, and Rit Define a Novel Subfamily of Ras Proteins , 1996, The Journal of Neuroscience.
[54] M. Wigler,et al. Stimulation of Membrane Ruffling and MAP Kinase Activation by Distinct Effectors of RAS , 1996, Science.
[55] S. Grzesiek,et al. NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.
[56] M. Wigler,et al. Multiple ras functions can contribute to mammalian cell transformation , 1995, Cell.
[57] J. Hancock,et al. Activation of Raf as a result of recruitment to the plasma membrane. , 1994, Science.
[58] Sally J. Leevers,et al. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane , 1994, Nature.
[59] G. Cooper,et al. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP , 1988, Molecular and cellular biology.
[60] G. N. Ramachandran,et al. Stereochemistry of polypeptide chain configurations. , 1963, Journal of molecular biology.
[61] D. Morrison,et al. Ras-Mediated Activation of the Raf Family Kinases. , 2019, Cold Spring Harbor perspectives in medicine.
[62] J. Haas,et al. Clinical outcomes associated with sarcomere mutations in hypertrophic cardiomyopathy: a meta-analysis on 7675 individuals , 2017, Clinical Research in Cardiology.
[63] D. Esposito,et al. Optimizing Expression and Solubility of Proteins in E. coli Using Modified Media and Induction Parameters. , 2017, Methods in molecular biology.
[64] K. Rauen,et al. The RASopathies. , 2013, Annual review of genomics and human genetics.
[65] Alex E. Lash,et al. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..
[66] G D'Hont,et al. [The Noonan syndrome]. , 1982, Acta oto-rhino-laryngologica Belgica.
[67] A. W. E. E. K. L. Y. J. O U R N A L D E V O T E D T O T H E A D V A N C E,et al. S C I E N C E , 2022 .